-
公开(公告)号：WO2023004266A1
公开(公告)日：2023-01-26
申请号：PCT/US2022/073780
申请日：2022-07-15
发明人： HAN, Xiaojun , ORR, Suvi, Tuula, Marjukka , BUNKER, Kevin, Duane , HUANG, Peter, Qinhua , FISCHER, Kimberlee
IPC分类号： C07D491/22 , C07K5/103 , A61K47/68 , A61K39/00 , A61K39/395 , A61P35/00 , C07K16/28 , A61K31/4745
摘要： Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
-
公开(公告)号：WO2021127045A1
公开(公告)日：2021-06-24
申请号：PCT/US2020/065410
申请日：2020-12-16
发明人： SAMATAR, Ahmed Abdi , LI, Jiali , IZADI, Hooman , HUANG, Peter Qinhua , PINCHMAN, Joseph Robert , BOREN, Brant Clayton , BUNKER, Kevin Duane , DONATE, Fernando
IPC分类号： A61K31/519 , A61P35/00
摘要： Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a Bcl-2 inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.
-
公开(公告)号：WO2019173082A8
公开(公告)日：2019-09-12
申请号：PCT/US2019/019557
申请日：2019-02-26
发明人： HUANG, Peter, Qinhua , BUNKER, Kevin, Duane , BOREN, Brant, Clayton , HEGDE, Sayee, Gajanan , LIU, Hui , UNNI, Aditya, Krishnan , ABRAHAM, Sunny , HOPKINS, Chad, Daniel , PALIWAL, Sunil
IPC分类号： C07D471/04 , A61P35/00 , A61K31/519
摘要： Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
-
公开(公告)号：WO2019139899A8
公开(公告)日：2019-07-18
申请号：PCT/US2019/012695
申请日：2019-01-08
发明人： PINCHMAN, Joseph, Robert , HUANG, Peter, Qinhua , BUNKER, Kevin, Duane , SIT, Rakesh, Kumar , SAMATAR, Ahmed, Abdi
IPC分类号： C07D471/04 , C07D491/107 , C07D471/14 , C07D211/46 , C07D295/155 , A61P31/18 , A61P35/00 , A61K31/437 , A61K31/5377 , A61K31/496 , A61K31/404
摘要： Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.
-
公开(公告)号：WO2022251224A1
公开(公告)日：2022-12-01
申请号：PCT/US2022/030739
申请日：2022-05-24
发明人： PINCHMAN, Joseph, Robert , NATALA, Srinivasa, Reddy , BUNKER, Kevin, Duane , HUANG, Peter, Qinhua
IPC分类号： A61K31/519 , A61P35/00 , C07D487/04 , C07D519/00
摘要： Compounds of general Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
-
公开(公告)号：WO2022140744A1
公开(公告)日：2022-06-30
申请号：PCT/US2021/072983
申请日：2021-12-17
IPC分类号： C07D471/04 , A61P35/00
摘要： Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as cancer. (Formula (I))
-
公开(公告)号：WO2022082180A1
公开(公告)日：2022-04-21
申请号：PCT/US2021/071840
申请日：2021-10-13
发明人： SAMATAR, Ahmed, Abdi , DONATE, Fernando , IZADI, Hooman , PINCHMAN, Joseph, Robert , BUNKER, Kevin, Duane , HUANG, Peter, Qinhua
IPC分类号： A61K31/496 , A61K31/5355 , A61K31/7068 , A61K31/4184 , A61K31/69 , A61P35/00 , A61P35/02
摘要： The present invention relates to the combination of Bcl-2 inhibitor Compound (A) in combination with a chemotherapeutic agent Compound (B) selected from azacitidine, bendamustine, bortezomib, carfilzomib, ixazomib, busulfan, carboplatin, cytarabine, cyclophosphamide, cladribine, cisplatin, capecitabine, decitabine, etoposide, fludarabine, gemcitabine, daunorubicin, doxorubicin, ifosfamide, methotrexate and vincristine, or a pharmaceutically acceptable salt of any of the foregoing, for the treatment of a disease or condition in particular hematological cancers.
-
公开(公告)号：WO2021127047A1
公开(公告)日：2021-06-24
申请号：PCT/US2020/065415
申请日：2020-12-16
发明人： SAMATAR, Ahmed, Abdi , LI, Jiali , MA, Jianhui , HUANG, Peter, Qinhua , HEGDE, Sayee, Gajanan , BOREN, Brant, Clayton , BUNKER, Kevin, Duane , DONATE, Fernando
IPC分类号： A61K31/519 , A61K31/437 , A61P35/00
摘要： Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.
-
公开(公告)号：WO2021127039A1
公开(公告)日：2021-06-24
申请号：PCT/US2020/065401
申请日：2020-12-16
发明人： SAMATAR, Ahmed, Abdi , LI, Jiali , HUANG, Peter, Qinhua , BOREN, Brant, Clayton , BUNKER, Kevin, Duane , DONATE, Fernando
IPC分类号： A61K31/519 , A61P35/00
摘要： Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a WEE1 inhibitor, and a SERD or SERM inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.
-
公开(公告)号：WO2021091819A
公开(公告)日：2021-05-14
申请号：PCT/US2020/058526
申请日：2020-11-02
发明人： HUANG, Peter, Qinhua , HEGDE, Sayee, Gajanan , BUNKER, Kevin, Duane , KNIGHT, John , SLEE, Deborah, Helen
IPC分类号： C07D471/04 , A61P35/00
摘要： Salts of Compound A and forms described herein are estrogen receptor alpha modulators. Such salts and/or forms can be are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.016 秒)
